Get started
Author

Brian S. Henick

LRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
2006 · Laurie J. Ozelius, Geetha Senthil, et al. · New England Journal of Medicine · 665
PDF
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
2022 · Biagio Ricciuti, Xinan Wang, et al. · JAMA Oncology · 378
PDF
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
2019 · K. Hastings, H.A. Yu, et al. · Annals of Oncology · 366
PDF
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
2019 · Ila Datar, Miguel F. Sanmamed, et al. · Clinical Cancer Research · 326
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy
2019 · Yuting Liu, Jon Zugazagoitia, et al. · Clinical Cancer Research · 322
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
2011 · Howard I. Scher, Xiaoyu Jia, et al. · Journal of Clinical Oncology · 249
PDF
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
2022 · Christine D. Palmer, Amy R. Rappaport, et al. · Nature Medicine · 236
PDF
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
2023 · Arvind Ravi, Matthew D. Hellmann, et al. · Nature Genetics · 188
PDF
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
2024 · Amy R. Rappaport, Chrisann Kyi, et al. · Nature Medicine · 152
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
2025 · Juanita Lopez, Thomas Powles, et al. · Nature Medicine · 118
PDF
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
2022 · Shoiab Bukhari, Brian S. Henick, et al. · Cell Reports Medicine · 86
PDF
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer
2019 · Jon Zugazagoitia, Yuting Liu, et al. · Journal of Thoracic Oncology · 75
PDF
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases
2025 · Somnath Tagore, Lindsay Caprio, et al. · Nature Medicine · 67
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
2020 · Juanita S. Lopez, Ross Camidge, et al. · Cancer Research · 59
Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens
2023 · Yiping Wang, Joy Linyue Fan, et al. · Nature Genetics · 57
PDF
A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2023 · Prabhjot S. Mundi, Filemon S. Dela Cruz, et al. · Cancer Discovery · 50
PDF
Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles
2024 · Xiao Cheng, Brian S. Henick, et al. · ACS Nano · 48
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
2014 · Brian S Henick, Roy S Herbst, et al. · Expert Opinion on Therapeutic Targets · 42
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer
2021 · Ila J. Datar, Sacha C. Hauc, et al. · Clinical Cancer Research · 39
PDF
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
2023 · Manish R. Patel, Dejan Juric, et al. · Journal of Clinical Oncology · 31
PDF
Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology
2020 · Susan J. Hsiao, Anthony N. Sireci, et al. · JCO Precision Oncology · 31
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
2020 · Biagio Ricciuti, Abdul Rafeh Naqash, et al. · JTO Clinical and Research Reports · 26
PDF
Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.
2010 · H. I. Scher, K. N. Chi, et al. · Journal of Clinical Oncology · 26
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
2025 · Breelyn A. Wilky, Gary K. Schwartz, et al. · Journal of Clinical Oncology · 23
PDF
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function
2022 · Afshin Dowlati, Ata Abbas, et al. · JCO Precision Oncology · 23
Works count: 253
Citation count: 4,081
H-index: 23
I10-index: 43
Year
Topic
Type